Belgium's Multiplicom Raises $2.9M to Pursue CE Mark for Breast Cancer, CF Tests

The University of Antwerp spinout's first significant investment will enable it to seek a CE Mark for in vitro diagnostic use of its multiplexed PCR assays for clinical breast cancer and cystic fibrosis sequencing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories